Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Marlins place struggling outfielder Avísail García on injured listSydney Sweeney puts on a busty display in a bikini top in highlights from her funJury finds Wisconsin man guilty in killing, sexual assault of 20Gladbach, Union Berlin draw 0Salma Hayek dresses up as Frida Kahlo to join Madonna on stage at her Mexico concertNicole Kidman wins AFI Life Achievement AwardBournemouth moves into top half of the Premier League after 3Senzel homers twice, Nationals erase 7Sydney Sweeney puts on a busty display in a bikini top in highlights from her funCubs place LHP Jordan Wicks on 15
2.5047s , 4667.671875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Glance news portal